TriSalus Life Sciences (TLSI) Common Equity (2020 - 2026)

TriSalus Life Sciences has reported Common Equity for 7 years, with the latest figure at $12.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 137.26% year-over-year to $12.8 million; the trailing twelve-month figure through Mar 2026 stood at $12.8 million (up 137.26% YoY), and the FY2025 full-year result was -$33.9 million, down 30.77% from the prior year.
• Common Equity for Q1 2026 stood at $12.8 million, up from -$33.9 million in the prior quarter.
• The five-year high for Common Equity was $12.8 million in Q1 2026, with the low at -$198.4 million in Q2 2023.
• Historically, Common Equity has averaged -$72.1 million across 5 years, with a median of -$33.9 million in 2025.
• Annual changes were most pronounced in 2022 — Common Equity plunged 684.82% — and 2026, when it surged 137.26%.
• TriSalus Life Sciences' Common Equity stood at -$177.1 million in 2022, then surged by 84.72% to -$27.1 million in 2023, then grew by 4.33% to -$25.9 million in 2024, then sank by 30.77% to -$33.9 million in 2025, then soared by 137.82% to $12.8 million in 2026.
• The last three Common Equity figures came in at $12.8 million (Q1 2026), -$33.9 million (Q4 2025), and -$26.7 million (Q3 2025), per Business Quant data.